Recommended articles Novel Anti-obesity Therapies and their Different Effects and Safety Profiles: A Critical Overview Telci Caklili O, Cesur M, Mikhailidis DP, Rizzo M Diabetes, Metabolic Syndrome and Obesity 2023, 16:1767-1774 Published Date: 14 June 2023 Relative Effectiveness and Safety of the GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists, Semaglutide and Liraglutide in the Treatment of Obese Type 2 Diabetics: A Prospective Observational Cohort Study in Poland Hoffmann K, Michalak M, Paczkowska A Diabetes, Metabolic Syndrome and Obesity 2025, 18:2723-2738 Published Date: 7 August 2025 Real-World Effectiveness and Safety of Tirzepatide, Semaglutide, and Liraglutide in Adults with Overweight or Obesity without Diabetes: A Comparative Study Cetiner S Diabetes, Metabolic Syndrome and Obesity 2026, 19:594898 Published Date: 31 March 2026 Exploring the Use of GLP-1-Based Interventions for Obesity: A Qualitative Analysis of ClinicalTrials.gov Data Alourfi NM, Alorfi NM Diabetes, Metabolic Syndrome and Obesity 2026, 19:575375 Published Date: 14 May 2026 Aesthetic Use of Poly-L-Lactic Acid and Hyaluronic Acid Fillers in Medication-Driven Weight Loss Due to GLP-1 Receptor Agonists: Real-World Case Series from Latin America Avelar LET, Sarlos P, Guarnieri C, Alvarez PP, Rojas GA, Rossiere N, Toro VA, Kamamoto C, Gomes RT, Nogueira A, Miot HA Clinical, Cosmetic and Investigational Dermatology 2026, 19:620566 Published Date: 17 June 2026
Getting that conversation on the calendar early puts you ahead of most of the paperwork
Figure 1 and Table 2 have been included to represent schematically IGF-1 actions in metabolism with target organs
If you are considering any peptide protocol, working with a regulated telehealth provider who can monitor bloodwork and flag risks is the only responsible approach
It mimics a hormone called GLP-1 that controls blood sugar levels in the body
